Current Licenses definition

Current Licenses means any agreement (a) that BioNTech or its Affiliates has entered into or enters into prior to the Effective Date with a Third Party and (b) pursuant to which BioNTech or its Affiliates are (i) granted rights to any BioNTech Technology as of the Effective Date or (ii) granted a license or otherwise transferred any right to practice under any Patent Rights or Know-How, in each case that relate to the Candidates or Products or activities under this Agreement. BioNTech’s Current Licenses are disclosed on Schedule 9.3.12.
View Source
Current Licenses means the petroleum exploration licenses 348/ "▇▇▇▇", 347/ "▇▇▇▇" and 388 / "▇▇▇▇▇▇".
View Source
Current Licenses means any agreement (a) that Codex or its Affiliates has entered into prior to the Effective Date and (b) pursuant to which Codex or its Affiliates are (i) granted rights to any Codex Technology as of the Effective Date or (ii) granted a license or otherwise transferred any right to practice under any Patent Rights or Know- How, in each case that are reasonably necessary to use the Deliverables or perform activities under this Agreement. 1.1.25. “Current Licensor” means any Third Party that is a party to a Current License. 1.1.26. “Deliverables” means any tangible Instrument, Method or other Know- How first made or developed by one or both Parties in the conduct of the Research Plan that are provided to Pfizer hereunder including in accordance with Section 2.11. 1.1.27. “Develop” or “Developing” means to discover, research or otherwise develop a process, compound or product, including conducting non-clinical and clinical research and development activities prior to Regulatory Approval. When used as a noun, “Development” means any and all activities involved in Developing. 1.1.28. “Development Milestone Payment” means any amounts payable by Pfizer upon achievement of any Development Milestones in accordance with Section 3.3.
View Source

Examples of Current Licenses in a sentence

  • Neither Seller has received (either directly or delivered to Existing Owner by Existing Operator) since January 1, 2011 any written notice from a governmental authority (including, without limitation, DSS) alleging any violation under any Current Licenses that has not been previously remedied or stating any intention to cancel, terminate, suspend, restrict or not renew any of the Current Licenses, and has not received any notices of informal conference or noncompliance conference.

  • BioNTech will maintain in full effect and will perform all of its obligations in a timely manner under each of the Current Licenses.

  • Depending on >ŝĐĞŶelƐectĞioĞn a͛t tƐhe time it purchased rights to use the Licensed Program, Southwire offers Licensed Program Maintenance to holders of Current Licenses on a ŽŶyĞeaͲr, ƚŚƌĞarĞ, oͲr ĨLJŝĞǀĞbͲasLJis.ĞĂƌ Payment of Maintenance Fees is required in order to obtain Maintenance for the Licensed Program, including Updates.

  • Each Party will be solely responsible for all obligations (including royalty and payment obligations) that relate to Candidates, Products, BioNTech Technology or Pfizer Technology under its or its Affiliates’ own agreements with Third Parties that are in effect on or prior to the Effective Date, including the Current Licenses for which BioNTech has sole responsibility.

  • BioNTech shall use reasonable efforts to obtain any reductions or waivers in royalties or other payments due under the Current Licenses that could constitute Third Party License Payments due to the pandemic status of COVID-19 or with respect to countries or populations experiencing emergency pandemic or crisis epidemic, coronavirus conditions, including taking into account any restrictions on pricing for the Product based on applicable Law and funding agreements with Third Party Funders.

  • Seller has not received since January 1, 2011 any written notice from a governmental authority (including, without limitation, the Department) alleging any violation under any Current Licenses that has not been previously remedied or stating any intention to cancel, terminate, suspend, restrict or not renew any of the Current Licenses, and has not received any notices of informal conference or noncompliance conference.

  • Except as set forth in Schedule 2.1(d), Sangamo will be solely responsible for (i) all obligations (including any royalty or other obligations that relate to the Licensed Technology) under the Current Licenses and under the Exclusive Upstream Licenses and (ii) all payments to inventors of Licensed Technology, including payments under inventorship compensation Laws.

  • Sangamo will be solely responsible for (i) all obligations (including any royalty or other obligations that relate to the Licensed Technology) under the Current Licenses and under the Exclusive Upstream Licenses and (ii) all payments to inventors of Licensed Technology, including payments under inventorship compensation Laws and (iii) all obligations, including but not limited to financial obligations, under any agreement between Sangamo and [*], which is identified in Exhibit I, related to [*].

  • Subject to Section 4.10, each Party will be solely responsible for all obligations (including royalty and payment obligations) that relate to Candidates, Products, BioNTech Technology or Pfizer Technology under its or its Affiliates' own agreements with Third Parties that are in effect on or prior to the Effective Date, including the Current Licenses for which BioNTech has sole responsibility.

  • Current Licenses Held: Auction Licenses: FL, GA, IN, ME, MA, NH, OH, PA, SC, TN, VT Business Licenses: DE, FL, WV Federal Firearms License (FFL): #6-16-029-01-5M-04024 Our executive leaders, President ▇▇▇▇ ▇.